• Cardiomyocytes Differentiation

Cardiomyocytes Differentiation

Applied StemCell, Inc. provides a comprehensive range of service to differentiate your iPSCs into cardiomyocytes using our proprietary induction protocol and reagents. We deliver ready to use, highly pure (>90%), functional cardiomyocytes. These differentiated cells provide a highly desirable in vitro platform for high content toxicity and drug screening and as a feasible alternative to animal and embryonic stem cell models. 

We can generate differentiated cardiomyocytes from your own pluripotent cell lines derived from healthy or disease iPSCs.

Products and Services
Support Materials
Technical Details

iPSC Differentiation to Cardiomyocytes


1. Recovery, Expansion and Validation of iPSCs/ESCs  (6 million cells), approx. 3 weeks

2. Cardiomyocytes Differentiation (5 x10^6 cells), approx. 2-4 weeks

3. Characterization of Progenitor Cells/ Differentiated Cells by ICC (2 markers: anti-TNT; anti-SMA staining) 2-4 days


1. 5 frozen vials of cardiomyocytes (1 million cells/vial). 

2. Report:

  • Phase contrast images of parental iPSC lines provided by the end user after expansion
  • Videos of beating cardiomyocytes differentiated from each parental line
  • ICC images (after thaw) of cardiomyocytes differentiated from each parental line provided by the end user. Cells stained for markers anti-TNT anti-SMA.
  • Freeze-thaw viability and mycoplasma testing

iPSC Differentiation to Blood Lineage Cells:

Ask us about directed differentiation of your iPSCs into hematopoietic stem cells (HSCs) and blood cells. Avoid sourcing problems associated with HSC procurement, and have a consistent and continuous source of mature human blood cells that are otherwise hard to obtain and maintain. 

Applications: hematopoiesis, cancer immunotherapy, autoimmune diseases/ transplant graft rejection, and drug screening.

Have Questions?

An Applied StemCell technical expert is happy to help, contact us today!